« Back
Home /
Narazaciclib

Narazaciclib

Manufacturer	MedChem Express
Category	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	10mM/1mL
Item no.	HY-12624-10mM
Targets	CDK; AMPK
CASRN	1357470-29-1
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Narazaciclib (ON123300), a strong and brain-penetrant[1] multi-kinase inhibitor, inhibits CDK4 (IC50=3.9 nM), Ark5 (IC50=5 nM), PDGFRβ (IC50=26 nM), FGFR1 (IC50=26 nM), RET (IC50=9.2 nM), and FYN (IC50=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors[2]. Narazaciclib inhibits CDK6 with an IC50 of 9.82 nM[3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	429.52
Clinical_Information	Phase 2
Manufacturers Research_Area	Cancer
Solubility	DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturers Target	AMPK; CDK; PDGFR
Isoform	CDK4; CDK6; NUAK1
Pathway	Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12624-10mM-safety-datasheet.pdf